Hypertension Clinical Trial
Official title:
An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension
| NCT number | NCT00624052 |
| Other study ID # | 1235.8 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 3 |
| First received | February 5, 2008 |
| Last updated | May 13, 2014 |
| Start date | March 2008 |
The primary objective of this trial is to assess the efficacy and safety of the fixed dose
combinations telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg
(T80/A10) during open-label treatment for at least six months.
An additional objective is to assess the efficacy and safety of concomitant administration
of either T40/A10 or T80/A10 with any other therapies commonly used in the treatment of
hypertension.
The primary endpoint is the proportion of patients achieving DBP control (defined as mean
seated DBP < 90 mmHg at trough i.e. approximately 24 hours after last dose of study
treatment) at six months of treatment or at last trough observation during the treatment
period (i.e. last trough observation carried forward).
| Status | Completed |
| Enrollment | 838 |
| Est. completion date | |
| Est. primary completion date | June 2009 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - diagnosis of essential hypertension Exclusion Criteria: - pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential). - development of any condition in the preceding trial that could be worsened by telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg (T80/A10). - discontinuation from the preceding trial. - known or suspected secondary hypertension. - mean seated systolic blood pressure (SBP) >= 180 mmHg and/or mean seated diastolic blood pressure (DBP) >= 120 mmHg at any visit. - any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant. - clinically relevant hyperkalaemia. - uncorrected volume or sodium depletion. - primary aldosteronism. - hereditary fructose or lactose intolerance. - symptomatic congestive heart failure. - patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). - any new drug or alcohol dependency since signing consent of the preceding trial. - concurrent participation in another clinical trial or any investigational therapy since completing the preceding trial. - hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve. - known allergic hypersensitivity to any component of the formulations under investigation. [Includes known hypersensitivity to telmisartan or other ARBs or amlodipine or other dihydropyridine calcium channel blockers (CCBs).] non-compliance with study medication (defined as <80% or >120%) during the preceding trial. - administration of ARBs or dihydropyridine CCBs (apart from trial medication). any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine. |
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Australia | 1235.8.61005 Boehringer Ingelheim Investigational Site | Elizabeth Vale | South Australia |
| Australia | 1235.8.61003 Boehringer Ingelheim Investigational Site | Gosford | New South Wales |
| Australia | 1235.8.61002 Boehringer Ingelheim Investigational Site | Kippa-Ring | Queensland |
| Australia | 1235.8.61004 Boehringer Ingelheim Investigational Site | Liverpool | New South Wales |
| Australia | 1235.8.61001 Boehringer Ingelheim Investigational Site | Milton | Queensland |
| Austria | 1235.8.43007 Boehringer Ingelheim Investigational Site | Eggenburg | |
| Austria | 1235.8.43006 Boehringer Ingelheim Investigational Site | Hainburg a.d. Donau | |
| Austria | 1235.8.43001 Boehringer Ingelheim Investigational Site | Wien | |
| Austria | 1235.8.43002 Boehringer Ingelheim Investigational Site | Wien | |
| Austria | 1235.8.43003 Boehringer Ingelheim Investigational Site | Wien | |
| Bulgaria | 1235.8.35912 Boehringer Ingelheim Investigational Site | Bourgas | |
| Bulgaria | 1235.8.35902 Boehringer Ingelheim Investigational Site | Sofia | |
| Bulgaria | 1235.8.35903 Boehringer Ingelheim Investigational Site | Sofia | |
| Bulgaria | 1235.8.35904 Boehringer Ingelheim Investigational Site | Sofia | |
| Bulgaria | 1235.8.35905 Boehringer Ingelheim Investigational Site | Sofia | |
| Bulgaria | 1235.8.35906 Boehringer Ingelheim Investigational Site | Sofia | |
| Bulgaria | 1235.8.35907 Boehringer Ingelheim Investigational Site | Sofia | |
| Bulgaria | 1235.8.35910 Boehringer Ingelheim Investigational Site | Sofia | |
| Bulgaria | 1235.8.35911 Boehringer Ingelheim Investigational Site | Sofia | |
| Czech Republic | 1235.8.42002 Boehringer Ingelheim Investigational Site | Benatky nad Jizerou | |
| Czech Republic | 1235.8.42006 Boehringer Ingelheim Investigational Site | Brno | |
| Czech Republic | 1235.8.42001 Boehringer Ingelheim Investigational Site | Plzen | |
| Czech Republic | 1235.8.42003 Boehringer Ingelheim Investigational Site | Praha 5 | |
| Czech Republic | 1235.8.42004 Boehringer Ingelheim Investigational Site | Pribram | |
| Czech Republic | 1235.8.42005 Boehringer Ingelheim Investigational Site | Slany | |
| Czech Republic | 1235.8.42007 Boehringer Ingelheim Investigational Site | Strakonice | |
| Ireland | 1235.8.35304 Boehringer Ingelheim Investigational Site | Birr | |
| Ireland | 1235.8.35305 Boehringer Ingelheim Investigational Site | Carrigtowhill | |
| Ireland | 1235.8.35303 Boehringer Ingelheim Investigational Site | Gorey, Co. Wexford | |
| Ireland | 1235.8.35306 Boehringer Ingelheim Investigational Site | Mallow | |
| Ireland | 1235.8.35301 Boehringer Ingelheim Investigational Site | New Ross | |
| Italy | 1235.8.39002 Boehringer Ingelheim Investigational Site | Broni (pv) | |
| Italy | 1235.8.39006 Boehringer Ingelheim Investigational Site | Coppito (AQ) | |
| Italy | 1235.8.39001 Boehringer Ingelheim Investigational Site | Ferrara | |
| New Zealand | 1235.8.64003 Boehringer Ingelheim Investigational Site | Dunedin | |
| New Zealand | 1235.8.64002 Boehringer Ingelheim Investigational Site | Otahuhu, Auckland | |
| New Zealand | 1235.8.64001 Boehringer Ingelheim Investigational Site | Tauranga | |
| Russian Federation | 1235.8.70004 Boehringer Ingelheim Investigational Site | Moscow | |
| Russian Federation | 1235.8.70005 Boehringer Ingelheim Investigational Site | Moscow | |
| Russian Federation | 1235.8.70006 Boehringer Ingelheim Investigational Site | Moscow | |
| Russian Federation | 1235.8.70007 Boehringer Ingelheim Investigational Site | Moscow | |
| Russian Federation | 1235.8.70008 Boehringer Ingelheim Investigational Site | Moscow | |
| Russian Federation | 1235.8.70009 Boehringer Ingelheim Investigational Site | Moscow | |
| Russian Federation | 1235.8.70010 Boehringer Ingelheim Investigational Site | St. Petersburg | |
| Russian Federation | 1235.8.70011 Boehringer Ingelheim Investigational Site | St. Petersburg | |
| Russian Federation | 1235.8.70012 Boehringer Ingelheim Investigational Site | St. Petersburg | |
| Slovakia | 1235.8.42103 Boehringer Ingelheim Investigational Site | Dolny Kubin | |
| Slovakia | 1235.8.42106 Boehringer Ingelheim Investigational Site | Kralovsky Chmlec | |
| Slovakia | 1235.8.42104 Boehringer Ingelheim Investigational Site | Liptovsky Mikulas | |
| Slovakia | 1235.8.42102 Boehringer Ingelheim Investigational Site | Povazska Bystrica | |
| Slovakia | 1235.8.42105 Boehringer Ingelheim Investigational Site | Presov | |
| Slovakia | 1235.8.42101 Boehringer Ingelheim Investigational Site | Trencin | |
| Slovakia | 1235.8.42107 Boehringer Ingelheim Investigational Site | Vrable | |
| Spain | 1235.8.34008 Boehringer Ingelheim Investigational Site | Badalona | |
| Spain | 1235.8.34010 Boehringer Ingelheim Investigational Site | Badalona | |
| Spain | 1235.8.34009 Boehringer Ingelheim Investigational Site | Barcelona | |
| Spain | 1235.8.34001 Boehringer Ingelheim Investigational Site | Jerez de la Frontera (Cádiz) | |
| Spain | 1235.8.34006 Boehringer Ingelheim Investigational Site | L'Hospitalet de Llobregat (Barcelona) | |
| Spain | 1235.8.34003 Boehringer Ingelheim Investigational Site | Madrid | |
| Spain | 1235.8.34004 Boehringer Ingelheim Investigational Site | Madrid | |
| Spain | 1235.8.34012 Boehringer Ingelheim Investigational Site | Mataró | |
| Spain | 1235.8.34002 Boehringer Ingelheim Investigational Site | Oviedo | |
| Spain | 1235.8.34005 Boehringer Ingelheim Investigational Site | Santa Coloma de Gramanet | |
| Spain | 1235.8.34011 Boehringer Ingelheim Investigational Site | Santa Coloma de Gramanet | |
| Ukraine | 1235.8.38010 Boehringer Ingelheim Investigational Site | Dnepropetrovsk | |
| Ukraine | 1235.8.38001 Boehringer Ingelheim Investigational Site | Kharkov | |
| Ukraine | 1235.8.38003 Boehringer Ingelheim Investigational Site | Kharkov | |
| Ukraine | 1235.8.38008 Boehringer Ingelheim Investigational Site | Kharkov | |
| Ukraine | 1235.8.38011 Boehringer Ingelheim Investigational Site | Kharkov | |
| Ukraine | 1235.8.38004 Boehringer Ingelheim Investigational Site | Kiev | |
| Ukraine | 1235.8.38006 Boehringer Ingelheim Investigational Site | Kiev | |
| Ukraine | 1235.8.38012 Boehringer Ingelheim Investigational Site | Kiev | |
| Ukraine | 1235.8.38013 Boehringer Ingelheim Investigational Site | Kiev | |
| Ukraine | 1235.8.38002 Boehringer Ingelheim Investigational Site | Lvov | |
| Ukraine | 1235.8.38005 Boehringer Ingelheim Investigational Site | Odessa | |
| Ukraine | 1235.8.38009 Boehringer Ingelheim Investigational Site | Odessa | |
| Ukraine | 1235.8.38007 Boehringer Ingelheim Investigational Site | Zaporozhye | |
| United Kingdom | 1235.8.44010 Boehringer Ingelheim Investigational Site | Bexhill on Sea | |
| United Kingdom | 1235.8.44008 Boehringer Ingelheim Investigational Site | Blackpool | |
| United Kingdom | 1235.8.44016 Boehringer Ingelheim Investigational Site | Blackpool | |
| United Kingdom | 1235.8.44011 Boehringer Ingelheim Investigational Site | Burbage | |
| United Kingdom | 1235.8.44007 Boehringer Ingelheim Investigational Site | Chestfield, Whitstable | |
| United Kingdom | 1235.8.44005 Boehringer Ingelheim Investigational Site | Chorley | |
| United Kingdom | 1235.8.44002 Boehringer Ingelheim Investigational Site | Edgbaston, Birmingham | |
| United Kingdom | 1235.8.44009 Boehringer Ingelheim Investigational Site | Ely | |
| United Kingdom | 1235.8.44001 Boehringer Ingelheim Investigational Site | Fowey | |
| United Kingdom | 1235.8.44003 Boehringer Ingelheim Investigational Site | Glasgow | |
| United Kingdom | 1235.8.44012 Boehringer Ingelheim Investigational Site | Penzance | |
| United Kingdom | 1235.8.44013 Boehringer Ingelheim Investigational Site | Plymouth | |
| United Kingdom | 1235.8.44004 Boehringer Ingelheim Investigational Site | Reading | |
| United Kingdom | 1235.8.44015 Boehringer Ingelheim Investigational Site | St. Austell | |
| United Kingdom | 1235.8.44006 Boehringer Ingelheim Investigational Site | Whitstable |
| Lead Sponsor | Collaborator |
|---|---|
| Boehringer Ingelheim |
Australia, Austria, Bulgaria, Czech Republic, Ireland, Italy, New Zealand, Russian Federation, Slovakia, Spain, Ukraine, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Trough Seated Diastolic Blood Pressure (DBP) Control | The number of patients who reached the target DBP of <90mmHg | End of study (34 weeks or last value on treatment) | No |
| Secondary | Trough Seated Systolic Blood Pressure (SBP) Control | The number of patients who reached the target SBP of >=140mmHg | End of study (34 weeks or last value on treatment) | No |
| Secondary | Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure | Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.6 | Baseline is defined as visit 3 of study NCT00553267 and end of study as 34 weeks or last value on treatment | No |
| Secondary | Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052 | The difference between the last available troughs represents the additional reduction in DBP in this study | Last available trough in NCT00553267 to end of study (34 weeks or last value on treatment) | No |
| Secondary | Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure | Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.6 | Baseline is defined as visit 3 of study NCT00553267 and end of study as 34 weeks or last value on treatment | No |
| Secondary | Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052 | The difference between the last available troughs represents the additional reduction in SBP in this study | Last available trough in NCT00624052 to end of study (34 weeks or last value on treatment) | No |
| Secondary | Trough Seated DBP Response | The number of patients who reach the target DBP of <90mmHg or had a reduction in DBP >= 10mmHg | End of study (34 weeks or last value on treatment) | No |
| Secondary | Trough Seated SBP Response | The number of patients who reach the target SBP of <140mmHg or had a reduction in SBP >= 15 mmHg | End of study (34 weeks or last value on treatment) | No |
| Secondary | Trough BP Normality Classes | The number of patients who reach predefined BP categories | End of study (34 weeks or last value on treatment) | No |
| Secondary | Time to First Additional Antihypertensive | Time from first intake of medication to first intake of an antihypertensive other than the study drug | up to 34 weeks | No |
| Secondary | Number of Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control | The number of patients with DBP control (DBP>=90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment | up to 34 weeks | No |
| Secondary | Additional Reduction in DBP by Use of Additional Antihypertensive Therapy | Difference in trough DBP from last visit before add-on therapy and last visit during NCT00624052 | up to 34 weeks | No |
| Secondary | Additional Reduction in SBP by Use of Additional Antihypertensive Therapy | Difference in trough SBP from last visit before add-on therapy and last visit during NCT00624052 | up to 34 weeks | No |
| Secondary | Trough DBP Control Pre- and Post- Uptitration | The number of patients with DBP control (DBP<90 mmHg). Last trough DBP measurement before uptitration to telmisartan 80mg and amlodipine 10mg compared to first trough DBP taken after uptitration. Uptitration could be based DBP>90 or investigator opinion. | up to 34 weeks | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
| Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
| Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
| Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
| Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
| Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
| Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
| Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
| Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
| Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
| Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
| Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
| Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |